

1 **Full Title:** Development and validation of a multiplex real-time qPCR assay using GMP-
2 grade reagents for leprosy diagnosis

3

4 **Short running head:** Multiplex qPCR for leprosy diagnosis

5

6 **Author names and affiliations.**

7 Fernanda Saloum de Neves Manta^{1¶}, Thiago Jacomasso^{2¶}, Rita de Cássia Pontello
8 Rampazzo², Suelen Justo Maria Moreira¹, Najua Zahra², Marcelo Ribeiro-Alves³, Marco
9 Aurélio Krieger^{2,4}, Alexandre Dias Tavares Costa^{2,4,&*}, Milton Ozório Moraes^{1&*}

10 ¹ Laboratório de Hanseníase, Instituto Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, Rio de
11 Janeiro, Brazil

12 ² Instituto de Biologia Molecular do Paraná, Fiocruz, Curitiba, Paraná, Brazil

13 ³ Instituto Nacional de Infectologia Evandro Chagas-Fiocruz, Rio de Janeiro, Rio de Janeiro,
14 Brazil

15 ⁴ Instituto Carlos Chagas, Fundação Oswaldo Cruz/FIOCRUZ, Curitiba, PR, Brasil.

16 ¶ These authors contributed equally to this work

17 & These authors also contributed equally to this work

18

19 *** Corresponding authors:**

20 1) Alexandre Dias Tavares Costa (Ph.D).

21 Instituto de Biologia Molecular do Paraná / Instituto Carlos Chagas, Fundação Oswaldo
22 Cruz/FIOCRUZ, Curitiba, Paraná, Brasil.

23 Phone: +55-41-3316-3230; E-mail: alexandre.costa@fiocruz.br

24

25 2) Milton Ozório Moraes (Ph.D).

26 Laboratório de Hanseníase, Instituto Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, Rio de
27 Janeiro, Brazil

28 E-mail: milton.moraes@fiocruz.br, Telephone contact: +55-21- 25621556.

29

30 Number of text pages (34); tables (4) and figures (7)

31

32 **Grant numbers and sources of support:**

33 This work was funded by a grants from: Banco Nacional de Desenvolvimento Econômico e
34 Social (BNDES), contract no. 15.2.0473.1 (Operation #4.816.864) to MAK, and Novartis
35 Foundation and Leprosy Research Initiative (LRI; 703.15.45), Foundation for Research
36 Support of the State of Rio de Janeiro (FAPERJ;E-26/203.053/2016), Brazilian National
37 Council for Scientific and Technological Development (CNPq; 421852/2017-2018), Brazilian
38 Coordination for Improvement of Higher Education Personnel (CAPES), and by the National
39 Fund for Health/Brazilian Ministry of Health (MS/SCTIE/DECIT; 404277/2012-8 and TED
40 145/2018) to MOM.

41

42

43 **Disclosure of conflict of interest**

44 Instituto de Biologia Molecular do Paraná (IBMP) produces the PCR mastermix and some
45 of the oligonucleotides used in the qPCR experiments. In addition, several authors received
46 grants or fellowships from the Brazilian funding agencies CNPq and CAPES. This work was
47 partially funded by grants from BNDES, Novartis Foundation, Leprosy Research Initiative,
48 Foundation for Research Support of the State of Rio de Janeiro (FAPERJ), CNPq, CAPES,
49 and by the National Fund for Health/Brazilian Ministry of Health (MS/SCTIE/DECIT).
50 However, none of the aforementioned institutions had any participation in the present study's
51 design, data collection, analysis, interpretation, or writing of the report and decision to submit
52 for publication.

53

54

55 **Abstract**

56

57 Leprosy is a chronic dermato-neurological disease caused by *Mycobacterium leprae*, an
58 obligate intracellular bacterium. Timely detection is a challenge in leprosy diagnosis, relying
59 on clinical examination and trained health professionals. Furthermore, adequate care and
60 transmission control depend on early and reliable pathogen detection. Here, we describe a
61 qPCR test for routine diagnosis of leprosy-suspected patients. The reaction simultaneously
62 amplifies two specific *Mycobacterium leprae* targets (16S rRNA and RLEP), and the human
63 18S rRNA gene as internal control. The limit of detection was estimated to be 2.29 copies
64 of *M. leprae* genome. Analytical specificity was evaluated using a panel of 20 other skin
65 pathogenic microorganisms and *Mycobacteria*, showing no cross-reactivity. Intra- and inter-
66 operator C_p variation was evaluated using dilution curves of *M. leprae* DNA or a synthetic
67 gene, and no significant difference was observed between three operators in two different
68 laboratories. The multiplex assay was evaluated using 97 patient samples with clinical and
69 histopathological leprosy confirmation, displaying high diagnostic sensitivity (91%) and
70 specificity (100%). Validation tests in an independent panel of 50 samples confirmed
71 sensitivity and specificity of 97% and 98%, respectively. Importantly, assay performance
72 remained stable for at least five months. Our results show that the newly developed
73 multiplex qPCR effectively and specifically detects *M. leprae* DNA in skin samples,
74 contributing to an efficient diagnosis that expedites the appropriate treatment.

75

76

77

78

79 **Author Summary**

80

81 Leprosy is a chronic dermato-neurological disease caused by *Mycobacterium leprae*, an
82 obligate intracellular bacterium. Disease diagnosis is currently performed on skin
83 examinations for clinical signs, bacilli staining in skin smears and invasive skin biopsies.
84 However, the spectrum of clinical manifestations and the low bacterial load can hinder
85 accurate diagnosis, which is critical for providing proper intervention and adequate care as
86 well as for establishing transmission control. Quantitative PCR (qPCR) methods for
87 detecting bacterial DNA are more sensitive and could aid in differentially diagnosing leprosy
88 from other dermatological conditions. In this work, we present a new multiplex qPCR that
89 detects two bacterial genes for the diagnosis and a human gene as an internal reaction
90 control. The new qPCR, developed using GMP-grade reagents, is highly sensitive, specific,
91 reproducible, and stable. The results presented here are the basis of a novel and robust tool
92 with potential to increase the accuracy of leprosy diagnosis in routine or reference
93 laboratories.

94

95 **Keywords**

96 leprosy; diagnostic; qPCR; good manufacturing practices; validation; neglected tropical
97 diseases; *Mycobacterium leprae*; internal control

99 Introduction

100

101 Leprosy is a neglected infectious disease that still represents a public health issue (1) with
102 more the 200,000 cases every year worldwide. Diagnosis is generally late and, although a
103 specific and effective treatment is available, it is likely that transmission occurs before the
104 patient is diagnosed and adequately treated, thus contributing to sustained transmission.
105 The high number of young patients (under 15 years old) and patients with disabilities due to
106 advanced stage of the disease, confirms this hypothesis (1). Furthermore, clinical forms
107 vary to a great extent, from localized (tuberculoid) to disseminated (lepromatous) forms,
108 making diagnosis difficult. Evidence suggests that early diagnosis could prevent
109 transmission and help epidemiological control (2).

110 Methods such as bacterial load detection by microscopy and histopathological examination
111 have been the main complementary tools for the diagnosis of leprosy (2–4). Classical
112 bacteriological methods cannot confirm leprosy since *M. leprae* does not grow *in vitro*. In
113 addition, there is no reliable marker to estimate the risk of disease progression (5,6). In this
114 regard, the sequencing of *M. leprae* genome (7) was a milestone towards the improvement
115 of direct *M. leprae* detection, leading not only to better characterization of genomic targets
116 unique to *M. leprae* strains but also to an extensive comparison of different mycobacteria.

117 At the time of the first sequences became available, the polymerase chain reaction (PCR)
118 technique was laborious and very expensive, averting its universal application. However, as
119 PCR was further developed, it became more affordable, versatile and reliable, with fully
120 automated systems becoming commercially available from different companies (8–10). For
121 tuberculosis, routine tests using PCR are reducing the turnaround time, allowing same day
122 treatment initialization, which might impact resistance prevalence (11–13). Cost-effective

123 nucleic acid detection assays are relatively widespread, but assays for some neglected
124 diseases are still missing. In leprosy, the situation is even more difficult due to reduced and
125 late investments directed to diagnostic tests (14).

126 In the last few years, many studies have been carried out using the PCR technique to detect
127 *M. leprae* DNA in clinical specimens. PCR have been used especially under challenging
128 diagnoses such as equivocal paucibacillary (4,15–18) or monitoring household contacts
129 (19,20). In this context, several different targets have been described in an attempt to
130 establish the most sensitive and specific assay (16,20–28). However, most of the PCR
131 protocols were developed, evaluated, and validated using reagents or tests produced
132 without good manufacturing practices (GMP). Also, most of the studies enroll only leprosy
133 patients and do not recruit patients with other common dermatological diseases that are
134 differential diagnosis to leprosy. Thus, the development and validation of an assay over
135 different laboratories has become a necessity.

136 Here, we present the development and validation of a multiplex real-time PCR assay aiming
137 to standardize the leprosy molecular diagnostic assay. The protocol was designed to
138 simultaneously detect two *M. leprae* targets (16SrRNA and RLEP genes), previously used
139 in several studies (4, 16, 19, 26, 29), and one mammalian target (18S rRNA gene), that serves
140 as reaction control (30). Cross-reactivity was evaluated using DNA from 20 related
141 mycobacterial and other skin pathogenic species, and no match was found. The new assay
142 was validated using 97 skin biopsies and an independent panel enrolling 50 samples
143 retrieved from patients previously characterized by clinical examination and histopathology,
144 showed high sensitivity and specificity. The new multiplex PCR was also assessed for
145 quality control standards and the data indicate that the assay is stable and reproducible. The
146 results presented here are the basis of a novel and robust tool with potential to increase the
147 accuracy of leprosy diagnosis in routine or reference laboratories.

148 **Material and methods**

149

150 **Ethics statement**

151 The Ethics Committee of the Oswaldo Cruz Foundation approved this study (CAAE:
152 38053314.2.0000.5248, number: 976.330–10/03/2015). Written informed consent was
153 obtained from all patients 18 years or older, or from the parents/guardian of patients under
154 18.

155

156 **Clinical samples**

157 Leprosy patients were enrolled from the Leprosy clinic from the Oswaldo Cruz Foundation
158 in the city of Rio de Janeiro, Brazil. Skin biopsies were collected using a 6-mm punch and
159 stored in 70% ethanol at -20 °C until processing.

160 Ninety-seven samples (53 skin biopsies from leprosy patients and 44 skin biopsies from
161 patients with other skin diseases) were used for qPCR tests. Clinical and demographic
162 characteristics of all patients are shown in Table 1.

163

164

165 **Table 1:** Clinical and demographic characteristics of the leprosy and other dermatological
166 disease cases

Characteristics	Types	1 st panel		2 nd panel	
		Leprosy group (n=53)	ODD group (n=44)	Leprosy group (n=35)	ODD group (n=15)
Gender	Male	32	13	25	3
	Female	21	31	10	12
Age	1-15	2	3	3	1
	16-30	8	7	5	2
	31-45	14	6	11	2
	46-60	20	19	9	9
	>60	9	9	7	1
WHO classification	PB	18	NA	8	NA
	MB	35	NA	27	NA
Clinical form	I	6	NA	0	NA
	TT	1	NA	3	NA
	BT	11	NA	5	NA
	BB	5	NA	6	NA

	BL	3	NA	7	NA
	LL	27	NA	14	NA
Bacterial load	0	23	38	8	15
	0-2	6	0	2	0
	2-4	11	0	13	0
	4-6	13	0	12	0

167 Other Dermatological Disease (ODD). Operational classifications [paucibacillary (PB) or multibacillary (MB)].
 168 PB individuals were classified as Tuberculoid (TT), Borderline tuberculoid (BT), Indeterminate (I) and Pure
 169 Neural (PN). MB individuals were classified as Borderline–borderline (BB), Borderline lepromatous (BL) or
 170 Lepromatous (LL). NA: Not Applicable.

171

172 Leprosy patients were defined according to the clinical, bacteriological, and
 173 histopathological Ridley-Jopling (R&J) classification and the operational classification in
 174 multibacillary (MB) or paucibacillary (PB) forms according to the WHO (31). Leprosy or other
 175 dermatological diseases (ODD) patients were treated according to their respective condition.
 176 Leprosy paucibacillary (PB) or multibacillary (MB) patients were treated according to the
 177 Ministry of Health recommendations, while ODD patients were treated accordingly for each
 178 specific disease.

179

180 **Replication Study**

181 To validate the conditions and analysis parameters established with the clinical samples
 182 from Oswaldo Cruz’s Leprosy Clinic, we tested a distinct collection of 50 skin biopsy samples
 183 that were also obtained by the Leprosy Clinic. The second set of samples was sent to the
 184 Global Health Institute, École Polytechnique Fédérale de Lausanne, Switzerland, where

185 DNA samples was extracted and was blindly characterized by conventional PCR according
186 to a previously published protocol (32). The extracted DNA was then sent back to the
187 Leprosy Clinic at Oswaldo Cruz Foundation, where it was blindly analyzed with the qPCR
188 developed in the present study. After both PCR analyses were performed, blinding was
189 removed and the results were compared. Of these 50 samples, fifteen samples were from
190 patients with other skin diseases, 27 patients MB leprosy and eight from PB leprosy. The
191 group presented a 1.27:1 ratio of males to females. The mean age was 44.8 (+/- 17.72 SD),
192 and the range was 8-77. Details on the clinical characteristics are shown in supplementary
193 table 1.

194

195 **Mycobacterial isolates samples**

196 *M. leprae* Thai-53 purified from athymic BALB/c (*nu/nu*) mouse footpads was kindly
197 provided by Dr. Patricia Rosa at the Lauro de Souza Lima Institute, Bauru, São Paulo, Brazil.
198 Purified DNA from *M. leprae* was used as positive control and in analytical sensitivity studies.
199 DNA from 21 mycobacterial samples were used for the analytical specificity study. *L.*
200 *amazonensis* and *L. braziliensis* was kindly provided by Dr Elisa Cupolillo by the Laboratório
201 de Pesquisa em Leishmaniose (IOC- Fiocruz) and *M. avium*, *M. gordonae*, *M. manteni*, *M.*
202 *africanum* subtype I, *M. africanum* subtype II, *M. bovis*, *M. bovis* (BCG), *M. canettii*, *M.*
203 *fortuitum*, *M. gordonae*, *M. intracellulare*, *M. kansasii*, *M. microti*, *M. pinnipedii*, *M. simiae*,
204 and *M. tuberculosis* were kindly provided by Dr. Phillip Suffys at Laboratório de Biologia
205 Molecular Aplicada a Micobactérias (IOC-Fiocruz).

206

207 **Synthetic DNA**

208 The synthetic DNA (gBlock®) was purchased from Integrated DNA Technologies (IDT) and
209 consists of a double-stranded DNA containing the sequences of the three genomic targets
210 (RLEP, 16S, and 18S) (S1 Appendix). The lyophilized DNA was reconstituted to 10 ng/μL
211 (corresponding to 1.83×10^9 copies per reaction) in TE pH 8.0, following the supplier's
212 protocol.

213

214 **DNA extraction**

215 DNA extraction from the biopsies was carried out using DNeasy Blood and Tissue®
216 extraction kit (Qiagen, Germany). The total extracted DNA was quantified with NanoDrop®
217 (Thermo-Fisher Scientific, Waltham, MA, USA) and stored at -20 °C. *M. leprae* DNA from
218 nude mice footpad was purified using TRIzol reagent (Life Technologies, Carlsbad,
219 California) following the manufacturers' instructions, as previously described (3). DNA used
220 in the replication study were extracted using QIAmp UCP Pathogen Mini kit (Qiagen GmbH,
221 Hilden, Germany).

222

223 **Standard curve and 95% limit of detection (LoD_{95%}) assessment**

224 The standard curve was used for determination of the limit of detection and assay stability.
225 A series of 10-fold dilutions was prepared from either *M. leprae* or synthetic DNA, using DNA
226 purified from human blood obtained from healthy donors as matrix. The dilution series used
227 for the standard curve and the LoD_{95%} determination spans concentrations from 500
228 ag/reaction to 5 ng/reaction of purified *M. leprae* DNA, and 1.83 to 1.83×10^7 copies/reaction
229 (equivalent to 0.5 ag/reaction and 5 pg/reaction, respectively) of synthetic DNA.

230

231 **Quantitative PCR (real-time PCR assays)**

232 A multiplex real-time qPCR assay targeting simultaneously two *M. leprae* regions and an
 233 internal reference human sequence was developed. The primers and hydrolysis probes
 234 were designed to detect regions from RLEP and 16S rRNA genes (29) from *M. leprae*, and
 235 the human 18S rRNA (30) (Table 2). Reactions were performed on an ABI7500 Standard
 236 instrument (Thermo-Fisher Scientific, Waltham, MA, USA), using Multiplex PCR Mastermix
 237 (IBMP/Fiocruz PR, Curitiba, Brazil). For each reaction, 5 µL of DNA solution was added for
 238 a 25 µL final volume. Reaction mixtures were prepared in triplicates and amplified at 95 °C
 239 for 10 min, and 45 cycles of 95 °C for 15 sec and 60 °C for 1 min. All reactions included a
 240 positive control (mouse foot-pad *M. leprae* DNA and/or high-bacterial load lepromatous
 241 leprosy patient purified DNA), and water as a non-template control (NTC; PCR reaction
 242 without any template DNA).

243

244 **Table 2:** Sequences, concentration, and fluorophores of the oligonucleotides contained in
 245 the multiplex qPCR assay.

Target	Sequences	Final concentration	Fluorophore
16SrRNA	Forward: 5'-GCATGTCTTGTGGTGGAAAGC- 3'	0.5 µM	FAM
	Reverse: 5'-CACCCCACCAACAAGCTGAT- 3'	0.5 µM	
	Probe: 5'-CATCCTGCACCGCA-3'	0.2 µM	
RLEP	Forward: 5'-GCAGCAGTATCGTGTTAGTGAA-3'	0.2 µM	VIC
	Reverse: 5'-CGCTAGAAGGTTGCCGTAT-3'	0.2 µM	
	Probe: 5'CGCCGACGGCCGGATCATCGA-3'	0.1 µM	
18s RNA	Forward: 5'-GAACTGCGAATGGCTCATTAATCA- 3'	0.06 µM	CY5
		0.06 µM	

	Reverse: 5'-CCCGTCGGCATGTATTAGCTCT-3'	0.03 μ M	
	Probe: 5'GGAGCGAGCGACCAAAGGAACCA-3'		

246

247

248 **Stability**

249 The stability of the new multiplex qPCR was evaluated the synthetic DNA template diluted
250 in TE to the concentrations of approximately 2×10^8 , 2×10^7 , 2×10^6 , 2×10^6 , 2×10^5 , $2 \times$
251 10^4 , 2×10^3 , 2×10^2 , 2×10^1 , 10, 5, and 2.5 copies per reaction.

252 All reagents (oligomix 25X and qPCR mix) were maintained in independent aliquots at -20
253 °C at the Leprosy Laboratory (Fiocruz-RJ). Tests with the dilution series described above
254 were repeated weekly for the first month, and then once a month for five months.

255

256 **Data Analyses and Statistics**

257 Qualitative (diagnostic sensitivity and specificity, accuracy) and quantitative (intra- and inter-
258 laboratory repeatability and reproducibility, analytical sensitivity and specificity) validation
259 tests were performed. The 95% limit of detection ($LoD_{95\%}$) was calculated by fitting a Probit
260 model to the estimated detection probabilities. Data were processed and analyzed using
261 customized scripts for R version 3.5.1 (downloaded from <http://www.Rproject.org/>).


263 Results

264

265 Analytical performance

266 Primers and hydrolysis probes designed to target 16S rRNA and RLEP sequences of *M.*
267 *leprae* were tested in multiplexed reactions to concomitantly detect the human 18S rRNA
268 sequence. Optimal fluorescence thresholds were chosen based on the common practice
269 that it should be positioned on the lower half of the fluorescence accumulation curves plot
270 from the 10-fold dilutions, crossing most if not all fluorescence signals on the exponential
271 segment of the curve on a logarithmic scale (figure 1). Therefore, after setting the baseline
272 to the automatic function, fluorescence threshold values chosen for determining C_p
273 (Crossing point) values for each target were set to intercept the positive controls and avoid
274 the negative ones, being established as follows: 0.2 for RLEP, 0.15 for 16S rRNA, and 0.16
275 for 18S rRNA.

276




277

278 **Fig 1. Standard curves of the amplification of 16SrRNA and RLEP targets in *M. leprae***
279 **DNA and in a synthetic construct.** Panels A and C show the calibration curves obtained
280 using *M. leprae* DNA, diluted in total DNA extracted from *M. leprae*-negative whole blood.
281 Continuous lines show the linear range and the dashed lines are extrapolations towards the
282 non-linear range. Efficiencies calculated from the linear ranges were 99.2% for 16SrRNA
283 and 102.2% for RLEP, and r^2 were 0.9968 and 0.9987, respectively. Panels B and D show
284 the calibration curves obtained using a synthetic gene containing one copy of each target
285 per molecule, diluted in total DNA extracted from *M. leprae*-negative whole blood. The
286 efficiencies were 94.9% for 16SrRNA and 93% for RLEP, and r^2 were 0.9874 and 0.9926,
287 respectively.

288

289 The analytical 95% limit of detection ($LoD_{95\%}$) was determined from a series of tests in which
290 DNA extracted from *M. leprae* was diluted from 5 ng to 100 ag/reaction. Figure 2 shows the
291 fitted Probit models and the obtained $LoD_{95\%}$ for 16S rRNA and RLEP, which were
292 experimentally determined as approximately 450 fg of DNA (ca. 126 *M. leprae* genomes) for
293 the 16SrRNA gene and about 4.60 fg of DNA (ca. 1.3 *M. leprae* genomes) for the RLEP
294 gene.

295



296


297 **Fig 2. Analytical 95% limit of detection (LoD_{95%}) for 16SrRNA and RLEP in multiplexed**
298 **qPCR.** *Mycobacterium leprae* DNA was diluted in DNA extracted from whole blood from
299 healthy donors and tested from 5 ng to 0.5 fg/reaction. Probability of detection was
300 calculated for 16S and RLEP (top and bottom panels, respectively) from nine independent
301 experiments, and a Probit model was fit to the data (black lines). The grey ribbon around
302 the model fit indicates the 95% CI on the predicted probability. Dotted lines indicate the

303 interpolation to determine the concentration at a 95% probability. The calculated $LoD_{95\%}$ is
304 displayed on each plot in femtograms of DNA/reaction.

305

306 The developed multiplex reaction was evaluated against a collection of microorganisms to
307 assess the specificity of the primers and probes under these conditions. The selection
308 included several mycobacteria, as well as a few other pathogens associated with skin
309 diseases such *Leishmania* (figure 3). We only considered any species as cross-reactive if
310 all the technical replicates displayed amplification for at least one of the targets which was
311 not the case for any of the species tested. Most positive amplifications observed correspond
312 to RLEP, which was detected in two out of three replicates in *M. fortuitum* and *M. kyroniense*.
313 Even though some reactions presented 16S rRNA signals above the threshold, these
314 amplifications are very uncharacteristic and are easily distinguishable from a proper
315 amplification when compared with the positive control with 500 fg/reaction of *M. leprae*.

316



317

318 **Fig 3. Analytical specificity for the 16SrRNA and RLEP multiplexed reactions.**

319 Extracted DNA from the indicated microorganisms (5 ng/ μ L each) were used in the

320 multiplexed reactions performed in technical triplicates in two independent experiments.
321 Results are compared to the amplification plot for 100 fg *M. leprae* DNA/ μ L (top-left panel).
322 Amplification profiles are shown for each target, and each line corresponds to one individual
323 well. The dotted lines indicate the threshold for RLEP (which is the highest of the two *M.*
324 *leprae* targets, at 0.2).

325

326 **Repeatability and reproducibility**

327 Three independent operators performed three replicate runs each, in consecutive days, and
328 evaluated the repeatability and reproducibility of the multiplex reactions. For each replicate,
329 a new dilution series for the synthetic gene was prepared from a concentrated aliquot to be
330 used as template. Table 3 shows the relative deviations observed within and between
331 operators, respectively. The data shows that all intra-operator replicates were remarkably
332 reproducible, with only one point (Op. 1, 16S, 1.83×10^2) displaying a relative standard
333 deviation (rRSD%) above 5%, but still well below 10%. The inter-operator variability was
334 also very low, and the largest variation was observed for the 16S target. Nonetheless, the
335 rRSD% was between 1.38 and 11.57 across the dilution range, which shows an excellent
336 reproducibility for a quantitative test (see also supplementary table 2).

337

338

339 **Table 3.** Precision measurement for repeatability and reproductibility.

Synthetic gene copies/reaction	Precision									Precision			
	Intra-operator (repeatability)									Inter-operator (reproductibility)			
	Operator 1			Operator 2			Operator 3			C _p mean	SD	rRSD%	
C _p mean	SD	rRSD%	C _p mean	SD	rRSD%	C _p mean	SD	rRSD%					
16S	1.83E+00	37.41	0.60	1.61	37.15	0.24	0.65	38.14	0.36	0.95	37.57	0.52	1.38
	1.83E+01	33.83	0.08	0.25	34.84	0.16	0.45	35.67	0.08	0.23	34.78	0.92	2.65
	1.83E+02	32.85	2.58	7.84	31.65	0.11	0.35	32.79	0.27	0.82	32.43	0.68	2.09
	1.83E+03	27.96	0.03	0.10	27.97	0.06	0.21	29.66	0.08	0.28	28.53	0.98	3.43
	1.83E+04	24.21	0.16	0.65	24.36	0.10	0.42	26.17	0.04	0.15	24.91	1.09	4.38
	1.83E+05	20.60	0.59	2.88	20.99	0.06	0.31	21.66	0.83	3.83	21.08	0.53	2.53
	1.83E+06	16.96	0.19	1.14	17.09	0.79	4.63	17.97	0.32	1.79	17.34	0.55	3.15
	1.83E+07	12.27	0.31	2.49	11.95	0.10	0.86	14.69	0.15	1.01	12.97	1.50	11.57
RLEP	1.83E+00	36.21	0.55	1.51	37.76	0.71	1.89	37.34	0.14	0.37	37.10	0.80	2.16
	1.83E+01	34.90	1.09	3.13	36.18	0.09	0.25	34.84	0.15	0.43	35.30	0.75	2.14
	1.83E+02	33.92	0.55	1.62	32.73	0.05	0.16	31.57	0.29	0.92	32.74	1.17	3.58
	1.83E+03	30.22	0.02	0.06	29.20	0.07	0.23	28.25	0.05	0.19	29.22	0.99	3.37
	1.83E+04	26.40	0.23	0.87	25.60	0.06	0.23	24.87	0.04	0.17	25.62	0.76	2.98
	1.83E+05	22.36	0.61	2.75	22.05	0.01	0.05	20.35	0.90	4.42	21.59	1.08	5.01
	1.83E+06	18.48	0.24	1.31	18.10	0.86	4.74	16.82	0.35	2.06	17.80	0.87	4.87
	1.83E+07	13.86	0.29	2.06	13.03	0.11	0.86	13.49	0.12	0.90	13.46	0.41	3.08

340

341 The accuracy of the determinations performed by the multiplex real-time qPCR assay was
 342 also estimated using the synthetic DNA. To evaluate the intra- and inter-repeatability (or
 343 intermediate precision) for operators, we calculated the arithmetic mean, standard deviation,

344 and relative standard deviation percentage of three independent experiments. It is
345 noteworthy that the detection of the human target 18S rRNA does follow the same dilution
346 trend for the other targets because the synthetic template was not diluted in human DNA.


347 In summary, for both *M. leprae* targets we observed that all points showed excellent
348 reproducibility and repeatability. As expected, detection of the human target 18SrRNA loses
349 reproducibility as it becomes scarce in the reaction due to the dilution factor. It is noteworthy
350 that there is no variation in the detection of the human target 18S rRNA when *M. leprae* DNA
351 was present in the synthetic control molecule, i.e., in a 1:1 ratio, supporting the notion that
352 the multiplexed reactions do not interfere with each other (data not shown).

353

354 **Stability**

355 Storage stability was assessed by performing monthly evaluations of reactions with different
356 concentrations of the synthetic DNA molecule for 5 months. Most of the data points tested
357 varied below the established limit of three standard deviations above the average of all time
358 points. Figure 4 shows the C_p obtained for the three evaluated targets (16SrRNA, RLEP,
359 and 18SrRNA) in representative concentrations for brevity, over a 5-month period. The test
360 remained reliable for the entire range of concentrations tested.

361



362

363 **Fig 4. Stability of the reactions over five months using synthetic DNA as a template.**


364 Each panel shows the C_p values obtained for each target (lines of panels) and for each
365 template concentration (columns of panels) over time. Points represent one technical
366 replicate. Black horizontal lines indicate the upper tolerance limit defined as three standard
367 deviations above the mean C_p for each template concentration.

368

369 Diagnostic performance

370 The implemented setup involved the interrogation of two target sequences from *M. leprae*
371 to classify clinical samples correctly while mitigating possible false positives. To evaluate
372 the diagnostic performance, we first established optimal parameters for the analysis,
373 considering possible cross-reactions that may occur in the laboratory routine. Figure 5
374 shows the receiver operating characteristic (ROC) curves for a subset of the best-performing
375 combinations of cutoff values for 16SrRNA and RLEP. Data for the full range of C_p cutoffs
376 combinations are listed in the supplementary table 3.

377



378

379 **Fig 5. Diagnostic performance of the new multiplex qPCR.** Different combinations of
380 cutoff values for 16SrRNA (panels) and RLEP (color scale) were tested on a patient panel
381 (n = 97). For each combination of cutoff values, the sensitivity and specificity were calculated
382 and plotted as ROC curves. Here, only C_p cutoff values for 16SrRNA between 35 and 36.5
383 are shown. The combinations resulting in a specificity of 1 and the highest sensitivity for
384 each condition are annotated.

385

386 Based on these results, the best combination of cutoff values (35.5 for 16SrRNA and 34.5
387 for RLEP) showed a sensitivity of 91% and specificity of 100%. These parameters were
388 used to establish the decision algorithm presented in Table 4.

389

390


391 **Table 4.** Decision algorithm for classification of samples based on the data obtained with
392 the new multiplex qPCR.

Results	Classification
18SrRNA negative	Extraction failure (repeat extraction)
18SrRNA C _p between 13 and 32	Valid reaction (proceed with classification)
RLEP < 34.5 and 16S < 35.5	<i>M. leprae</i> detected
RLEP < 34.5 and 16S ≥ 35.5	Equivocal (mark patient for new sample collection and testing)
RLEP ≥ 34.5	<i>M. leprae</i> undetected

393

394 Next, the molecular diagnosis obtained using the new multiplex PCR, was compared to the
395 clinical diagnosis of each sample (Figure 6 and supplementary table 4). Results show that
396 the qPCR reaction and classification algorithm correctly characterized 48 of the 53 samples
397 previously described as "Leprosy" by the clinical outcome. Of the 5 misclassified samples,
398 one was classified as negative for *M. leprae* and four were in the "equivocal" quadrant. The
399 Bacterial load for the 5 misclassified samples were 0.

400



401

402 **Fig 6. Distribution of C_p values obtained for the training panel.** Each point represents a
 403 different sample (mean C_p s of a technical duplicate). Filled circles represent leprosy samples
 404 and open dots represent negative samples, as defined by the clinical assessment. Points
 405 aligned to the top and right margins indicate samples in which 16SrRNA or RLEP,
 406 respectively, were not detected within 45 cycles. Bacterial load is shown as a color gradient
 407 (samples for which bacterial load information was not available are filled in grey). Dotted red
 408 lines indicate the cutoff values from Table 3. Equivocal or misclassified samples are
 409 annotated with the operational classification (false negatives) or with the diagnosis for clinic-
 410 negative samples.

411


412 None of the 44 samples characterized as "Other skin diseases" were classified as *M. leprae*-
413 positive by our reaction and decision algorithm. Thirty-eight of these samples were classified
414 as "Negative" and 6 as "equivocal".

415

416 Assay validation

417 Conditions established with the training cohort were tested on an independent set of
418 samples, which were previously characterized using a distinct qPCR method described in
419 Girma et al. (32). The comparison between the original classification and the new results is
420 shown in figure 7 and supplementary table 1. We tested 50 samples, of which 34 were
421 previously characterized as positive and 16 as negative.

422



423

424 **Fig 7. Validation of parameters on a in an independent panel.** Previously characterized
425 validation samples were subjected to the new qPCR described in the present study. Each
426 point represents a different sample. Filled circles represent leprosy samples and open dots
427 represent negative samples, as defined by Girma *et al.* Points aligned to the top and right
428 margins indicate samples in which 16SrRNA or RLEP, respectively, were not detected within
429 45 cycles. Bacterial load is show as a color gradient (samples for which bacterial load
430 information was not available are filled in grey). Dotted red lines indicate the cutoff values
431 from Table 3.

432

433 The 50 samples were classified according to our algorithm, resulting in 33 correctly classified
434 as positive and 11 correctly classified as negative. Of the four samples classified as
435 equivocal, two were negative for the reference method and one was positive according to
436 Girma et al (32). The sensitivity, specificity and accuracy calculated for this sample set were
437 97.1%, 100% and 98%, respectively.

438 Discussion

439

440 Leprosy is a chronic infectious disease presenting great diversity of clinical forms with
441 distinct immunological and histopathological features. Leprosy can be tuberculoid, which is
442 a localized form exhibiting few or no bacteria, or lepromatous, which is a systemic form with
443 high loads of mycobacteria. Among the tuberculoid patients, there is a range of skin
444 granulomatous diseases phenotypically comparable to leprosy (5).

445 The use of PCR for leprosy diagnosis has been extensively tested (4,16,33–44). However,
446 limitations towards the experimental designs for some published studies were identified. We
447 observed that most studies: (i) test only samples from leprosy patients, creating difficulties
448 in determining some diagnostic parameters such as specificity; (ii) were performed on small
449 sample sizes; and (iii) do not have independent validation on the same assay or an
450 evaluation of the same protocol in different centers. Furthermore, no studies have used
451 reagents produced under good manufacturing practices (GMP), a set of guidelines that allow
452 for traceability and batch-to-batch reproducibility of characteristics such as physical
453 parameters and performance of the reagents (45).

454 In this study, we solved some of these issues by (i) developing and validating an assay
455 based on the two most tested targets in the literature with better accuracy so far (7,8,41,46),
456 (ii) following guidelines for validation of diagnostic tests (45,47,48), and (iii) using GMP grade
457 reagents. We were also able to include a reaction for the detection of human 18S gene in
458 the sample, to assess the quality of DNA extraction and reagents performance in the same
459 reaction as the *M. leprae* determination occurs.

460 RLEP and 16SrRNA are the most frequent markers used in leprosy studies, displaying PCR
461 sensitivity values up to 80% for each target. However, it is important to note that the

462 sensitivity of targets varied between sample types, clinical settings, and also between
463 studies of the same authors (8,9). Tatipally et al. (9) showed that using more than one
464 marker in a multiplex format of conventional endpoint PCR yields significantly higher PCR
465 positivity.

466 In the currently study, a multiplex qPCR assay simultaneously amplifies two specific
467 *Mycobacterium leprae* targets (16SrRNA and RLEP), and the mammalian 18SrRNA gene
468 as internal reaction control. The assay validation comprised analytical performance,
469 diagnostic sensitivity and specificity, as well as reproducibility and repeatability.
470 Development of multiplex qPCR assays provides a greater challenge than designing
471 singleplex assays because it often requires extensive optimization as primer-dimers and
472 non-specific interactions may interfere with amplification of the desired targets. Additionally,
473 it is important that the amplification of two or more targets does not preferentially amplify
474 one of the targets (49,50). Combining multiple primers and probes did not affect the
475 efficiency of the triplex qPCR in comparison to the corresponding singleplex reactions used
476 in Martinez et al. (16), who evaluated the independent detection of 16S and RLEP using the
477 same primers and probes and obtained 0.91 and 0.51 for sensitivity and 0.73 and 1 for
478 specificity, respectively. Barbieri et al. (4) also used the same 16S target to evaluate
479 paucibacillary leprosy samples and obtained 0.57 for sensitivity and 0.91 for specificity.
480 Here, we evaluated a panel with 53 leprosy and 44 non-leprosy patient samples, and later
481 a different sample panel (50 patient samples) and achieved high sensitivity (> 90%) and
482 specificity (100%) for both panels tested.

483 However, we understand that the small number of paucibacillary (PB) individuals in our
484 study is a limitation. In fact, the greatest importance of using qPCR as a complementary
485 diagnosis is precisely for PB samples. Generally, PB patients exhibit low (or zero) bacterial
486 load and a histopathology examination that does not distinguish from the diagnosis of other

487 dermatoses. Therefore, these are the cases where clinical evaluation alone might not be
488 able to determine the diagnosis, and where a qPCR confirmation becomes more important.
489 However, due to the scarcity of bacterial DNA in these sample, it is known that the detection
490 of *M. leprae* in PB patients by real-time PCR is difficult (4).

491 The reactions we developed in this study predict the equivocal classification of early-stage
492 infections based on the finding from Martinez et al. (16), who showed that RLEP displays
493 higher sensitivity than 16S whereas the ribosomal gene displays higher specificity. Thus,
494 samples lacking 16S amplification but with RLEP amplification with a C_p lower than the
495 threshold are suggested to be re-analyzed.

496 In general, our data (figure 6) show a correlation between BI and C_p values. Biopsies from
497 patients with higher BI values were deemed positive for bacteria earlier in the amplification
498 cycle, as seen by the lower C_p values and high copy numbers of bacilli.

499 The “analytical sensitivity” or “limit of detection” of an assay is defined as the ability of the
500 assay to detect very low concentrations of a given substance in a biological specimen (45).

501 The result of the limit of detection ($LoD_{95\%}$) determination when tested on a purified *M. leprae*
502 sample indicated a higher sensitivity for RLEP (4.6 fg of DNA/reaction, equivalent to
503 approximately 1.3 *M. leprae* genomes) versus 16S (450 fg of DNA/reaction, approximately
504 126 *M. leprae* genomes). This difference in sensitivity was expected since the 16SrRNA is
505 a single copy gene (29) and the RLEP presents an average of 36 copies per genome (26).

506 Applicability in a reference laboratory setting was also considered during the development
507 of these reactions. Intra and inter-operator variability were low, ensuring consistent results
508 in routine testing (table 3). Moreover, reagents remained stable for at least five months,
509 allowing for adequate stock maintenance (figure 4).

510 Leprosy is a silent disease with a very long incubation time. Currently, transmission can only
511 be halted if patients obtain early diagnosis. High-risk individuals, which are the patients'
512 close contacts, should be traced and treated whenever leprosy is detected. Recently, it has
513 been suggested that novel policies towards this group of contacts such as immuno- and
514 chemoprophylaxis are effective to help control the disease burden (15,51,52). These
515 approaches provide a screening of the high-risk population that, coupled with a
516 pharmacological or immunological intervention, has been suggested to decrease disease
517 incidence.

518 In some situations, clinical diagnosis needs the accuracy support of a laboratory analysis,
519 and qPCR is a reliable technique to enable diagnostic confirmation (10). Indeed, we
520 confirmed that the availability of molecular tests can be very helpful in diagnosing patients
521 during contact monitoring (53). When contacts present a leprosy-like lesion, a positive PCR
522 resulted in a leprosy diagnosis with 50% sensitivity and 94% specificity (53). Other indirect
523 methods based on simultaneous detection of host humoral as well as cellular immune
524 response directed against the bacteria are also promising new diagnostic tools. Recently,
525 lateral flow assays (LFA), combining detection of mycobacterial components and host
526 proteins, proved to be specific and sensitive (54–60). The signature detected by this platform
527 identified 86% of the leprosy patients, with a specificity of 90% (AUC: 0.93, $p < 0.0001$) (58).
528 Thus, a multicentric study comparing different available methods such as qPCR and LFA is
529 still necessary. It is noteworthy that our data showed accuracy, sensitivity, and specificity
530 values quite similar to LFA.

531 We believe that the diagnosis of tropical and neglected diseases needs molecular-based
532 methods such as PCR, especially due to the robustness and capillarity of the technique in
533 clinical analysis laboratories worldwide. Towards that future, we present a real-time
534 quantitative PCR produced with GMP reagents that adheres to all quality control

535 specifications, allowing batch-to-batch performance reproducibility and repeatability, and
536 that can be used in research and clinical laboratories with reasonable infrastructure in
537 endemic countries. Finally, we envision the multiplex qPCR assay developed adapted to
538 more affordable, rapid, point-of-care tests to be used in low-resourced settings, enabling on-
539 site early and specific diagnosis of leprosy, hopefully helping disease control.

540

541 **Acknowledgments**

542 The authors are grateful to the entire team of dermatologists, nurses, and technicians that
543 collaborate at the Souza Araújo Clinic from the Leprosy Laboratory at the Oswaldo Cruz
544 Institute. The authors are also grateful for the excellent technical assistance by Aline Burda
545 Farias, Nilson José Fidêncio and Sylvia Mara Bohn at IBMP. We thank the Laboratório de
546 Pesquisa em Leishmaniose (IOC- Fiocruz) and Laboratório de Biologia Molecular Aplicada
547 a Micobactérias (IOC-Fiocruz) for donating the DNA from mycobacterial samples used in
548 the analytical specificity study.

549

550 **References**

551

- 552 1. WHO | A guide for surveillance of antimicrobial resistance in leprosy: 2017 update.
553 <https://www.who.int/lep/resources/9789290226192/en/>
- 554 2. Sarno EN, Duppre NC, Sales AM, Hacker MA, Nery JA, Matos HJ de. Leprosy
555 exposure, infection and disease: a 25-year surveillance study of leprosy patient
556 contacts. *Mem Inst Oswaldo Cruz*. 2012 Dec;107(8):1054–9.
- 557 3. Shepard CC, McRae DH. A method for counting acid-fast bacteria. *Int J Lepr Other*
558 *Mycobact Dis*; 36(1):78–82.
- 559 4. Barbieri RR, Manta FSN, Moreira SJM, Sales AM, Nery JAC, Nascimento LPR, et al.
560 Quantitative polymerase chain reaction in paucibacillary leprosy diagnosis: A follow-
561 up study. *PLoS Negl Trop Dis*. 2019;13(3):e0007147.
- 562 5. Reibel F, Cambau E, Aubry A. Update on the epidemiology, diagnosis, and treatment
563 of leprosy. *Med Mal Infect*. 2015;45(9):383–93.
- 564 6. White C, Franco-Paredes C. Leprosy in the 21st century. *Clin Microbiol Rev*.
565 2015;28(1):80–94.
- 566 7. Cole ST, Eiglmeier K, Parkhill J, James KD, Thomson NR, Wheeler PR, et al. Massive
567 gene decay in the leprosy bacillus. *Nature*; 409(6823):1007–11.
- 568 8. Goulart IMB, Goulart LR. Leprosy: Diagnostic and control challenges for a worldwide
569 disease. *Arch Dermatol Res*. 2008;300(6):269–90.
- 570 9. Tatipally S, Srikantam A, Kasetty S. Polymerase Chain Reaction (PCR) as a Potential
571 Point of Care Laboratory Test for Leprosy Diagnosis—A Systematic Review. *Trop*
572 *Med Infect Dis*. 2018;3(4):107.

- 573 10. Kralik P, Ricchi M. A basic guide to real time PCR in microbial diagnostics: Definitions,
574 parameters, and everything. *Front Microbiol.* 2017;8(FEB):1–9.
- 575 11. Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, et al. Rapid
576 Molecular Detection of Tuberculosis and Rifampin Resistance. *N Engl J Med.* 2010
577 Sep 9;363(11):1005–15.
- 578 12. Scott L, David A, Govender L, Furrer J, Rakgokong M, Waja Z, et al. Performance of
579 the Roche Cobas MTB Assay for the Molecular Diagnosis of Pulmonary Tuberculosis
580 in a High HIV Burden Setting. *J Mol Diagnostics.* 2020;22(10):1225-1237.
- 581 13. Silva Feliciano C, José Bazzo Menon L, Maria Pala Anselmo L, Dippenaar A, Mark
582 Warren R, Araújo Silva Jr W, et al. Xpert MTB/RIF performance to diagnose
583 tuberculosis and rifampicin resistance in a reference centre in southern Brazil. 2019
584 Aug 5;5(3):00043-2019.
- 585 14. Fonseca B de P, Albuquerque PC, Zicker F. Neglected tropical diseases in Brazil: lack
586 of correlation between disease burden, research funding and output. *Trop Med Int*
587 *Heal.* 2020 ;25(11):1373-1384
- 588 15. Steinmann P, Reed SG, Mirza F, Hollingsworth TD, Richardus JH. Innovative tools
589 and approaches to end the transmission of *Mycobacterium leprae*. *Lancet Infect Dis.*
590 2017 Sep;17(9):e298–305.
- 591 16. Martinez AN, Lahiri R, Pittman TL, Scollard D, Truman R, Moraes MO, et al.
592 Evaluation of qPCR-Based assays for leprosy diagnosis directly in clinical specimens.
593 *J Clin Microbiol.* 2011 Jul 1;5(10):1–8.
- 594 17. Nobre ML, Amorim FM, de Souza MCF, de Neves-Manta FS, Esquenazi D, Moraes
595 MO, et al. Multibacillary leprosy and the elderly: A field for further research. *Lepr Rev.*

596 2017;88(4):510–9.

597 18. da Silva Martinez T, Nahas AA, Figueira MMR, Costa A V., Gonçalves MA, Goulart
598 LR, et al. Oral lesion in leprosy: Borderline tuberculoid diagnosis based on detection
599 of mycobacterium leprae DNA by qPCR. *Acta Derm Venereol.* 2011;91(6):704–7.

600 19. Gama RS, Gomides TAR, Gama CFM, Moreira SJM, de Neves Manta FS, de Oliveira
601 LBP, et al. High frequency of *M. leprae* DNA detection in asymptomatic household
602 contacts. *BMC Infect Dis.* 2018;18(1):153.

603 20. Reis EM, Araujo S, Lobato J, Neves AF, Costa AV, Gonçalves MA, et al.
604 *Mycobacterium leprae* DNA in peripheral blood may indicate a bacilli migration route
605 and high-risk for leprosy onset. *Clin Microbiol Infect.* 2014 ;20(5):447–52.

606 21. Goulart IMB, Cardoso AM, Santos MS, Gonçalves MA, Pereira JE, Goulart LR.
607 Detection of *Mycobacterium leprae* DNA in skin lesions of leprosy patients by PCR
608 may be affected by amplicon size. *Arch Dermatol Res.* 2007;299(5–6):267–71.

609 22. Caleffi KR, Hirata RDC, Hirata MH, Caleffi ER, Siqueira VLD, Cardoso RF. Use of the
610 polymerase chain reaction to detect *Mycobacterium leprae* in urine. *Brazilian J Med*
611 *Biol Res.* 2012;45(2):153–7.

612 23. Maltempe FG, Baldin VP, Lopes MA, Siqueira VLD, Scodro RBDL, Cardoso RF, et al.
613 Critical analysis: Use of polymerase chain reaction to diagnose leprosy. *Brazilian J*
614 *Pharm Sci.* 2016;52(1):163–9.

615 24. Azevedo M de CS, Ramuno NM, Fachin LRV, Tassa M, Rosa PS, Belone A de FF, et
616 al. qPCR detection of *Mycobacterium leprae* in biopsies and slit skin smear of different
617 leprosy clinical forms. *Brazilian J Infect Dis.* 2017;21(1):71–8.

618 25. Arunagiri K, Sangeetha G, Sugashini PK, Balaraman S, Showkath Ali MK. Nasal PCR

- 619 assay for the detection of *Mycobacterium leprae* pra gene to study subclinical infection
620 in a community. *Microb Pathog*. 2017;104:336–9.
- 621 26. Truman RW, Andrews PK, Robbins NY, Adams LB, Krahenbuhl JL, Gillis TP.
622 Enumeration of *Mycobacterium leprae* Using Real-Time PCR. Small PLC, editor.
623 *PLoS Negl Trop Dis*. 2008 Nov 4;2(11):e328.
- 624 27. Banerjee S, Sarkar K, Gupta S, Mahapatra PS, Gupta S, Guha S, et al. Multiplex PCR
625 technique could be an alternative approach for early detection of leprosy among close
626 contacts - a pilot study from India. *BMC Infect Dis*. 2010;10:1–8.
- 627 28. Donoghe HD, Holton J, Spigelman M. PCR primers that can detect low levels of
628 *Mycobacterium leprae* DNA. *J Med Microbiol*. 2001;50(2):177–82.
- 629 29. Martinez AN, Lahiri R, Pittman TL, Scollard D, Truman R, Moraes MO, et al. Molecular
630 Determination of *Mycobacterium leprae* Viability by Use of Real-Time PCR. *J Clin*
631 *Microbiol*. 2009;47(7):2124–30.
- 632 30. Manta FS de N, Leal-Calvo T, Moreira SJM, Marques BLC, Ribeiro-Alves M, Rosa
633 PS, et al. Ultra-sensitive detection of *Mycobacterium leprae*: DNA extraction and PCR
634 assays. Poonawala H, editor. *PLoS Negl Trop Dis*. 2020;14(5):e0008325.
- 635 31. Ridley D, Jopling W. Classification of leprosy according to immunity. A five-group
636 system. *Int J Lepr Other Mycobact Dis*. 1966;34(3):255–73.
- 637 32. Girma S, Avanzi C, Bobosha K, Desta K, Idriss MH, Busso P, et al. Evaluation of
638 Auramine O staining and conventional PCR for leprosy diagnosis: A comparative
639 cross-sectional study from Ethiopia. *PLoS Negl Trop Dis*. 2018;12(9):1–14.
- 640 33. Kramme S, Bretzel G, Panning M, Kawuma J, Drosten C. Detection and quantification
641 of *Mycobacterium leprae* in tissue samples by real-time PCR. *Med Microbiol Immunol*.

- 642 2004;193(4):189–93.
- 643 34. Patrocínio LG, Goulart IMB, Goulart LR, Patrocínio JA, Ferreira FR, Fleury RN.
644 Detection of *Mycobacterium leprae* in nasal mucosa biopsies by the polymerase chain
645 reaction. *FEMS Immunol Med Microbiol*. 2005;44(3):311–6.
- 646 35. Phetsuksiri B, Rudeeaneksin J, Supapakul P, Wachapong S, Mahotarn K, Brennan PJ.
647 A simplified reverse transcriptase PCR for rapid detection of *Mycobacterium leprae* in
648 skin specimens. *FEMS Immunol Med Microbiol*. 2006;48(3):319–28.
- 649 36. Da Cunha FMB, Werneck MCM, Scola RH, Werneck LC. Pure neural leprosy:
650 Diagnostic value of the polymerase chain reaction. *Muscle and Nerve*.
651 2006;33(3):409–14.
- 652 37. Santos AR, De Miranda AB, Sarno EN, Suffys PN, Degraive WM. Use of PCR-
653 mediated amplification of *Mycobacterium leprae* DNA in different types of clinical
654 samples for the diagnosis of leprosy. *J Med Microbiol*. 1993 Oct 1;39(4):298–304.
- 655 38. Scollard DM, Gillis TP, Williams DL. Polymerase chain reaction assay for the detection
656 and identification of *Mycobacterium leprae* in patients in the United States. *Am J Clin*
657 *Pathol*. 1998 May;109(5):642–6.
- 658 39. Martinez AN, Britto CFPC, Nery JAC, Sampaio EP, Jardim MR, Sarno EN, et al.
659 Evaluation of real-time and conventional PCR targeting complex 85 genes for
660 detection of *Mycobacterium leprae* DNA in skin biopsy samples from patients
661 diagnosed with leprosy. *J Clin Microbiol*. 2006;44(9):3154–9.
- 662 40. Rudeeaneksin J, Srisungngam S, Sawanpanyalert P, Sittiwakin T, Likanonsakul S,
663 Pasadorn S, et al. LightCycler™ real-time PCR for rapid detection and quantitation of
664 *Mycobacterium leprae* in skin specimens. *FEMS Immunol Med Microbiol*.

- 665 2008;54(2):263–70.
- 666 41. Martinez AN, Talhari C, Moraes MO, Talhari S. PCR-Based Techniques for Leprosy
667 Diagnosis: From the Laboratory to the Clinic. Franco-Paredes C, editor. PLoS Negl
668 Trop Dis. 2014 Apr 10;8(4):e2655.
- 669 42. Tiwari V, Malhotra K, Khan K, Maurya PK, Singh AK, Thacker AK, et al. Evaluation of
670 polymerase chain reaction in nerve biopsy specimens of patients with Hansen’s
671 disease. J Neurol Sci. 2017;380:187–90.
- 672 43. Carvalho RS, Foschiani IM, Renata M, Nogueira S, Marta SN. Early detection of M .
673 leprae by qPCR in untreated patients and their contacts : results for nasal swab and
674 palate mucosa scraping Early detection of M . leprae by qPCR in untreated patients
675 and their contacts : results for nasal swab and palate mucosa sc. Eur J Clin Microbiol
676 Infect Dis. 2018 Oct;37(10):1863-1867.
- 677 44. Woods SA, Cole ST. A rapid method for the detection of potentially viable
678 Mycobacterium leprae in human biopsies: a novel application of PCR. FEMS Microbiol
679 Lett. 1989 Dec;53(3):305–9.
- 680 45. Burd EM. Validation of laboratory-developed molecular assays for infectious diseases.
681 Clin Microbiol Rev. 2010;23(3):550–76.
- 682 46. Turankar RP, Pandey S, Lavania M, Singh I, Nigam A, Darlong J, et al. Comparative
683 evaluation of PCR amplification of RLEP, 16S rRNA, rpoT and Sod A gene targets for
684 detection of M. leprae DNA from clinical and environmental samples. Int J
685 Mycobacteriology. 2015;4(1):54–9.
- 686 47. Mattocks CJ, Morris MA, Matthijs G, Swinnen E, Corveleyn A, Dequeker E, et al. A
687 standardized framework for the validation and verification of clinical molecular genetic

- 688 tests. Eur J Hum Genet. 2010;18(12):1276–88.
- 689 48. National Association of Testing Authorities A (NATA). Guidelines for the validation and
690 verification of chemical methods. 2013;(December 2006:1–6.
- 691 49. Markoulatos P, Siafakas N, Moncany M. Multiplex polymerase chain reaction: A
692 practical approach. J Clin Lab Anal. 2002;16(1):47–51.
- 693 50. Lorenz TC. Polymerase Chain Reaction: Basic Protocol Plus Troubleshooting and
694 Optimization Strategies. J Vis Exp. 2012;63:3998.
- 695 51. Gillini L, Cooreman E, Wood T, Pemmaraju VR, Saunderson P. Global practices in
696 regard to implementation of preventive measures for leprosy. Phillips RO, editor. PLoS
697 Negl Trop Dis. 2017;11(5):e0005399.
- 698 52. Richardus JH, Tiwari A, Barth-jaeggi T, Arif MA, Banstola NL, Baskota R, et al.
699 Leprosy post-exposure prophylaxis with single-dose rifampicin (LPEP): an
700 international feasibility programme. 2020;(20):10–4.
- 701 53. Manta FSN, Barbieri RR, Moreira SJM, Santos PTS, Nery JAC, Duppre NC, et al.
702 Quantitative PCR for leprosy diagnosis and monitoring in household contacts: A
703 follow-up study, 2011–2018. Sci Rep. 2019 Dec 1;9(1):1–8.
- 704 54. Bobosha K, Tjon Kon Fat EM, van den Eeden SJF, Bekele Y, van der Ploeg-van Schip
705 JJ, de Dood CJ, et al. Field-Evaluation of a New Lateral Flow Assay for Detection of
706 Cellular and Humoral Immunity against Mycobacterium leprae. PLoS Negl Trop Dis.
707 2014;8(5).
- 708 55. Van Hooij A, Fat EMTK, Van Den Eeden SJF, Wilson L, Da Silva MB, Salgado CG, et
709 al. Field-friendly serological tests for determination of M. Leprae-specific antibodies.
710 Sci Rep . 2017;7(1):1–8.

- 711 56. Yang S, Rothman RE. PCR-based diagnostics for infectious diseases: uses,
712 limitations, and future applications in acute-care settings. *Lancet Infect Dis.*
713 2004;4(6):337–48.
- 714 57. Corstjens PLAM, van Hooij A, Tjon Kon Fat EM, Alam K, Vrolijk LB, Dlamini S, et al.
715 Fingertstick test quantifying humoral and cellular biomarkers indicative for *M. leprae*
716 infection. *Clin Biochem.* 2019;66:76–82.
- 717 58. Van Hooij A, Van Den Eeden S, Richardus R, Tjon E, Fat K, Wilson L, et al. Application
718 of new host biomarker profiles in quantitative point-of-care tests facilitates leprosy
719 diagnosis in the field. *EBioMedicine.* 2019;47:301–8.
- 720 59. van Hooij A, Tió-Coma M, Verhard EM, Khatun M, Alam K, Tjon Kon Fat E, et al.
721 Household Contacts of Leprosy Patients in Endemic Areas Display a Specific Innate
722 Immunity Profile. *Front Immunol.* 2020;11:1–12.
- 723 60. Ti O-Coma M, Kie»basa SM, Van Den Eeden SJF, Mei H, Roy JC, Wallinga J, et al.
724 Blood RNA signature RISK4LEP predicts leprosy years before clinical onset-NC-ND
725 license *EBioMedicine.* 2021;68:103379.
- 726
- 727

728 **Supplementary Appendix 1.** Sequences of the synthetic DNA template control.

729

730 **Supplementary Table 1.** Validation multiplex real-time qPCR assay study results.

731

732 **Supplementary Table 2.** Reproducibility and Repeatability results from synthetic DNA.

733

734 **Supplementary Table 3.** List of C_p cutoff value combinations with associated sensitivity and
735 specificity scores.

736

737 **Supplementary Table 4.** Individual Ct values for targets included in the multiplex real-time
738 qPCR assay (16S rRNA/RLEP/18SrRNA), sociodemographic, and laboratory variables for
739 patients samples included in this study.

740

741

742 **Author's contributions**

743

744 F.S.N.M., T.J. Wrote the manuscript and contributed equally for this study;


745 F.S.N.M., T.J., R.C.P.R., N.Z., S.M., M.R.A. designed, performed, and analyzed
746 experiments;

747 F.S.N.M., M.O.M. supervised sample collection;


748 T.J., A.D.T.C. supervised production of kit prototypes;

749 M.A.K., M.O.M. secured funding;


750 A.D.T.C., M.O.M. conceptualized the study and approved the final version of the manuscript
751 and are co-senior authors of this study. Guarantors of the integrity of the data presented.




Figure




Figure



Figure




Figure



Figure

16S Undetected Other skin diseases


medRxiv preprint doi: <https://doi.org/10.1101/2021.10.04.21264517>; this version posted October 5, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).



Figure

16S Undetected

medRxiv preprint doi: <https://doi.org/10.1101/2021.10.04.21264517>; this version posted October 5, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).



Figure